TD Cowen names UnitedHealth its 2027 best idea, upgrades shares

TD Cowen upgraded UnitedHealth Group to Buy, naming it its 2027 Best Idea. The brokerage raised its price target to $455, citing improved earnings outlook and stronger margins. It expects adjusted EPS to grow to $23.57 in 2027 and $27.61 in 2028, driven by Optum Health recovery and Medicare Advantage profitability.

Original reporting
Published Nov 20, 2026, 8:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$UNH
Bullish
high confidence
Mentioned
$UNH
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$UNHBullishMed
01

Why it matters

The key trading hook is the combination of an upgrade, a raised price target, and a detailed multi-year earnings/margin bridge that can influence short-term positioning and expectations.

02

Market read

For traders, this is a sentiment and expectations reset anchored to Optum Health margin recovery and higher modeled EPS through 2028.

03

What to watch

Regulatory and reimbursement dynamics in Medicare Advantage and Medicaid, plus execution risk in Optum Rx/Insight growth, could limit the realized path to mid-to-high-teens earnings growth.

Relevance 7/10Novelty 5/10Timing: today, post-upgrade positioning and target-driven sentiment

Background

TD Cowen’s note reframes UnitedHealth’s earnings outlook around Optum Health stabilization and margin normalization across insurance and government programs.

Company-level read

Ticker impact

$UNHBullishHigh confidence
Context

TD Cowen upgraded UnitedHealth to Buy and named it its 2027 Best Idea, citing an improving earnings outlook tied to Optum Health recovery and margin gains.

Expected impact

Likely upward bias as traders price in the revised earnings trajectory and higher target, though follow-through depends on whether the market already anticipated the Optum recovery.

Evidence & confidence

The article contains a concrete analyst action (upgrade plus raised price target) and a specific earnings bridge (Optum Health margin expansion and profitability recovery) that can drive near-term sentiment and positioning.

Market effects

Reinforces positive read-through for managed care and Optum-linked earnings durability, potentially supporting sentiment across large US health insurers.

primarily US large-cap healthcare sentiment; limited direct cross-region impact.

modest, as the catalyst is company-specific analyst guidance rather than a global policy or macro shock.

Counterpoint

The upgrade may be more about analyst modeling than new company disclosures; if Optum margin recovery or Medicare Advantage profitability faces headwinds, the thesis could unwind.

Key entities

  • UnitedHealth Group

    Subject of the analyst upgrade and Best Idea call, with thesis centered on Optum Health recovery and margin expansion.

  • TD Cowen

    Brokerage issuing the Buy upgrade, raised price target, and 2027 Best Idea designation.

Related articles

$UNHMed

UnitedHealth Stock (UNH) Rises After the Healthcare Company Filed a Lawsuit Against the U.S. Government

UnitedHealth (UNH) stock rose 4.61% after filing a lawsuit against the U.S. government over a star rating drop by the Centers for Medicare & Medicaid Services, claiming improper measures were used. The company seeks higher ratings for 45 contracts, potentially increasing them by 0.5 to 1.5 stars. Analyst Ryan Langston upgraded UNH to Buy with a $455 price target, citing strong earnings growth.

$UNHMed

UnitedHealth sues US government over lowered Medicare Advantage star ratings

UnitedHealth Group sued the US government over its 2027 Medicare Advantage star ratings, claiming improper calculations could reduce bonus payments and patient benefits. The company, the largest Medicare Advantage insurer, said ratings for 45 contracts would rise if calculated correctly. CMS declined to comment. Other insurers, including CVS Health, have also sued over their ratings.

$UNHMed

Cowen Upgrades UNH and HUM Stocks to Buy and Lifts Price Targets After Healthcare Sell-Off. Here’s Why

Cowen upgraded UnitedHealth (UNH) and Humana (HUM) to Buy, citing strong earnings growth prospects. Analyst Ryan Langston raised UNH's price target to $455 and HUM's to $485. Both stocks rose in pre-market trading after a healthcare sector sell-off due to proposed CMS regulations. Cowen expects UNH's EPS to grow mid-high teens through 2028 and HUM's to reach $40.42 by 2028.

$UNHMed

UnitedHealth sues to reverse downgraded Medicare Advantage quality scores

UnitedHealth Group sued the U.S. government over lowered Medicare Advantage star ratings for 2027, joining 14 other insurers. The company, the largest Medicare Advantage insurer, claims the ratings calculation is inconsistent and unfairly reduces scores below bonus thresholds. Medicare Advantage plans are rated on a scale of one to five stars, with higher ratings earning bonus payments.